Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Iterum Therapeutics PLC is a biotechnology business based in the US. Iterum Therapeutics shares (ITRM) are listed on the NASDAQ and all prices are listed in US Dollars. Iterum Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.21 |
|---|---|
| 52-week range | $0.18 - $1.49 |
| 50-day moving average | $0.23 |
| 200-day moving average | $0.39 |
| Wall St. target price | $1.00 |
| PE ratio | 0.8536 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.25 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.213 from 2022-07-01
| 1 week (2022-06-29) | -3.66% |
|---|---|
| 1 month (2022-06-06) | -5.79% |
| 3 months (2022-04-05) | -37.81% |
| 6 months (2022-01-06) | -48.05% |
| 1 year (2021-07-06) | -83.36% |
|---|---|
| 2 years (2020-07-06) | -81.95% |
| 3 years (2019-07-03) | 6.64 |
| 5 years (2017-07-02) | N/A |
Valuing Iterum Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Iterum Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Iterum Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Iterum Therapeutics shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $37,000 |
|---|---|
| Return on assets TTM | -16.35% |
| Return on equity TTM | 9.62% |
| Profit margin | 0% |
| Book value | $0.27 |
| Market capitalisation | $39.1 million |
TTM: trailing 12 months
We're not expecting Iterum Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Iterum Therapeutics's shares have ranged in value from as little as $0.175 up to $1.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iterum Therapeutics's is 1.2017. This would suggest that Iterum Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.